Spirecut has launched a funding campaign with Capital Cell to drive the next phase of growth and development for its pioneering ultra-minimally invasive surgical instruments. Since entering the market in early 2024, Spirecut has achieved CE marking and FDA listing, allowing it to bring its products to key markets in Switzerland, Ireland, the UK, the U.S., and Canada. Through Capital Cell, Europe’s leading investment platform for health startups, Spirecut aims to raise €800,000 to expand its international presence and further develop its product portfolio.

Investors interested in supporting Spirecut’s mission can participate in this funding round through Capital Cell. For more information, visit Capital Cell’s platform and register to access detailed information about this opportunity.